InvestorsHub Logo
Followers 36
Posts 2818
Boards Moderated 0
Alias Born 02/12/2017

Re: None

Tuesday, 03/31/2020 7:47:20 AM

Tuesday, March 31, 2020 7:47:20 AM

Post# of 5007
PR Newswire
March 31, 2020, 6:30 am
Animal studies show a complete and statistically significant (p <0.0001) inhibition of tumor growth

MARLBOROUGH, Mass., March 31, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced data from various animal studies validating the potential of Phio's INTASYL technology as a cancer immunotherapy platform for developing novel compounds. The preclinical findings, which will be presented in further detail at upcoming scientific conferences, demonstrate that the INTASYL-enabled compounds can effectively be used to reduce immunosuppression in the tumor microenvironment (TME), which is one of the key challenges for many other immunotherapy platforms to achieve an adequate therapeutic effect in solid tumors.


https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/phio-announces-positive-data-validating-113000532.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PHIO News